COMP <GO>
CRMD vs ZVRA // EV/EBITDA & P/E VALUATION
CorMedix Inc. (NASDAQ) VS. Zevra Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CRMD 3
— ZVRA 2
■ METRIC PARITY
LAST: $7.64 (-6.83%) • MKT CAP: $595.5M
valuation
3.0x
LAST: $10.36 (+0.49%) • MKT CAP: $615.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRMD VS. ZVRA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRMD | ZVRA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 45.50% | -32.30% | +77.80 | CRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 3.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -0.40% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 48.20% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 52.30% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.81 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | CRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.3 | 45.7 | -20.39 | ZVRA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | 6.9x | -3.40 | CRMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $595.5M | $615.2M | -$19.7M | ZVRA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRMD REV | ZVRA REV | CRMD GROSS % | ZVRA GROSS % | CRMD FCF | ZVRA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $311.7M | $0 | 88.5% | — | $172.8M | -$2.4M |
| FY 2024 | $43.5M | $0 | 92.7% | — | -$50.7M | -$69.7M |
| FY 2023 | $0 | $0 | — | — | -$38.4M | -$33.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRMD // BETA —
ZVRA // BETA —